Controversy surrounding two new diet drugs, Belviq (lorcaserin) and Qsymia (phentermine plus topiramate), is at the forefront of medical headlines and dieters are urged to evaluate the benefits versus the potential health risks when making the decision to use these diet aids. Although recently approved for use in the United States, As Medical News Today reports, Europe considers these diet drugs too harmful to be marketed. Dr. Sidney Wolfe, founder of the health research group at Public Citizen, states that, after clinical trials, these drugs were approved in America despite vast cardiovascular concerns. During trials, patients were observed to have increases in pulse of more than 10 beats per minute, which is a significant risk factor for cardiovascular disease, as well as potential arrhythmia related concerns, impaired memory and reduced concentration. The diet drugs were also associated with a 16% increase in heart valve damage.